Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic
Tashkent, Uzbekistan – The pharmaceutical firm Geropharm, based in Russia, has successfully registered Semavik in Uzbekistan. This drug, featuring the active component semaglutide, is designed for managing both type 2 diabetes and obesity.
According to the company's press release, Semavik represents the first Russian-produced biosimilar to the Danish medication Ozempic, and it is currently accessible to patients. Health tracking apps like Shotlee can help monitor effectiveness of such medications.
Data from the World Health Organization indicates that approximately 30% of Uzbekistan's population, equating to nearly one in three residents, is affected by obesity. Furthermore, the International Diabetes Federation reported that diabetes cases in the country reached 1.5 million in 2024.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Geropharm's representatives have pointed out that these statistics underscore the increasing strain of metabolic disorders on the healthcare infrastructure and reinforce the demand for readily available and effective treatment alternatives.
Prior to this, Geropharm had already secured registration for Semavik in Azerbaijan, Kazakhstan, and Tajikistan.
